1. Investors can lead a class action securities fraud lawsuit against HIMS. 2. The lawsuit alleges misleading statements about partnerships and product safety. 3. Claims include promotion of illegitimate medical products impacting patient safety. 4. Investors must act before August 25, 2025, to participate. 5. Negative publicity may impact HIMS's stock performance and investor confidence.
The class action lawsuit indicates potential legal and financial repercussions for HIMS. Similar cases have led to significant stock declines in the past, such as with companies like Theranos.
The lawsuit is likely to significantly impact public perception and stock price due to the allegations of securities fraud.
Immediate investor sentiment may decline due to the lawsuit's impact. Historical examples show that such lawsuits create quick sell-offs in affected stocks.
LOS ANGELES, Aug. 7, 2025 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Hims & Hers Health, Inc. ("Hims" or the "Company") (NYSE: HIMS).
IF YOU SUFFERED A LOSS ON YOUR HIMS INVESTMENTS, CLICK HERE BEFORE AUGUST 25, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT
What Is The Lawsuit About?
The complaint filed alleges that, between April 29, 2025 and June 23, 2025, Defendants failed to disclose to investors: (1) that Hims was engaged in the "deceptive promotion and selling of illegitimate, knockoff versions of Wegovy that put patient safety at risk;" (2) that, as a result, there was a substantial risk that the Company's collaboration with Novo Nordisk would be terminated; and (3) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Contact Us To Participate or Learn More:
If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us.
Charles Linehan, Esq.,
Glancy Prongay & Murray LLP,
1925 Century Park East, Suite 2100,
Los Angeles California 90067
Email: shareholders@glancylaw.com
Telephone: 310-201-9150 (Toll-Free: 888-773-9224)
Visit our website at www.glancylaw.com.
Follow us for updates on LinkedIn, Twitter, or Facebook.
If you inquire by email, please include your mailing address, telephone number and number of shares purchased.
To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contact Us:
Glancy Prongay & Murray LLP,
1925 Century Park East, Suite 2100,
Los Angeles, CA 90067
Charles Linehan
Email: shareholders@glancylaw.com
Telephone: 310-201-9150
Toll-Free: 888-773-9224
Visit our website at: www.glancylaw.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/hims--hers-health-inc-hims-investors-who-lost-money-have-opportunity-to-lead-securities-fraud-lawsuit-302524650.html
SOURCE Glancy Prongay & Murray LLP